Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Identifieur interne : 003585 ( PubMed/Curation ); précédent : 003584; suivant : 003586Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Auteurs : Jens Büntzel [Allemagne] ; Michael Glatzel ; Ralph Mücke ; Oliver Micke ; Frank BrunsSource :
- Anticancer research [ 0250-7005 ]
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Amifostine (usage thérapeutique), Antinéoplasiques (effets indésirables), Facteurs temps, Femelle, Humains, Lymphoedème (), Lymphoedème (traitement médicamenteux), Mâle, Radioprotecteurs (usage thérapeutique), Radiothérapie (effets indésirables), Sténose de l'oesophage (), Sténose de l'oesophage (traitement médicamenteux), Sujet âgé, Sujet âgé de 80 ans ou plus, Troubles de la déglutition (), Troubles de la déglutition (traitement médicamenteux), Troubles du goût (), Troubles du goût (traitement médicamenteux), Tumeurs de la tête et du cou (), Xérostomie (), Xérostomie (traitement médicamenteux), Études de suivi.
- MESH :
- effets indésirables : Antinéoplasiques, Radiothérapie.
- traitement médicamenteux : Lymphoedème, Sténose de l'oesophage, Troubles de la déglutition, Troubles du goût, Xérostomie.
- usage thérapeutique : Amifostine, Radioprotecteurs.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Lymphoedème, Mâle, Sténose de l'oesophage, Sujet âgé, Sujet âgé de 80 ans ou plus, Troubles de la déglutition, Troubles du goût, Tumeurs de la tête et du cou, Xérostomie, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Amifostine (therapeutic use), Antineoplastic Agents (adverse effects), Deglutition Disorders (chemically induced), Deglutition Disorders (drug therapy), Esophageal Stenosis (chemically induced), Esophageal Stenosis (drug therapy), Female, Follow-Up Studies, Head and Neck Neoplasms (therapy), Humans, Lymphedema (chemically induced), Lymphedema (drug therapy), Male, Middle Aged, Radiation-Protective Agents (therapeutic use), Radiotherapy (adverse effects), Taste Disorders (chemically induced), Taste Disorders (drug therapy), Time Factors, Xerostomia (chemically induced), Xerostomia (drug therapy).
- MESH :
- chemical , adverse effects : Antineoplastic Agents.
- chemical , therapeutic use : Amifostine, Radiation-Protective Agents.
- adverse effects : Radiotherapy.
- chemically induced : Deglutition Disorders, Esophageal Stenosis, Lymphedema, Taste Disorders, Xerostomia.
- drug therapy : Deglutition Disorders, Esophageal Stenosis, Lymphedema, Taste Disorders, Xerostomia.
- therapy : Head and Neck Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Time Factors.
Abstract
The late toxicities due to multimodal therapy of advanced head and neck cancers were analysed. The impact of cytoprotection with amifostine is the specific objective of this report.
PubMed: 17649803
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003585
Links to Exploration step
pubmed:17649803Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.</title>
<author><name sortKey="Buntzel, Jens" sort="Buntzel, Jens" uniqKey="Buntzel J" first="Jens" last="Büntzel">Jens Büntzel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen, Nordhausen, Germany. jens.buentzel@shk-ndh.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen, Nordhausen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Glatzel, Michael" sort="Glatzel, Michael" uniqKey="Glatzel M" first="Michael" last="Glatzel">Michael Glatzel</name>
</author>
<author><name sortKey="Mucke, Ralph" sort="Mucke, Ralph" uniqKey="Mucke R" first="Ralph" last="Mücke">Ralph Mücke</name>
</author>
<author><name sortKey="Micke, Oliver" sort="Micke, Oliver" uniqKey="Micke O" first="Oliver" last="Micke">Oliver Micke</name>
</author>
<author><name sortKey="Bruns, Frank" sort="Bruns, Frank" uniqKey="Bruns F" first="Frank" last="Bruns">Frank Bruns</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2007 Jul-Aug</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:17649803</idno>
<idno type="pmid">17649803</idno>
<idno type="wicri:Area/PubMed/Corpus">003585</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003585</idno>
<idno type="wicri:Area/PubMed/Curation">003585</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003585</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.</title>
<author><name sortKey="Buntzel, Jens" sort="Buntzel, Jens" uniqKey="Buntzel J" first="Jens" last="Büntzel">Jens Büntzel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen, Nordhausen, Germany. jens.buentzel@shk-ndh.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen, Nordhausen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Glatzel, Michael" sort="Glatzel, Michael" uniqKey="Glatzel M" first="Michael" last="Glatzel">Michael Glatzel</name>
</author>
<author><name sortKey="Mucke, Ralph" sort="Mucke, Ralph" uniqKey="Mucke R" first="Ralph" last="Mücke">Ralph Mücke</name>
</author>
<author><name sortKey="Micke, Oliver" sort="Micke, Oliver" uniqKey="Micke O" first="Oliver" last="Micke">Oliver Micke</name>
</author>
<author><name sortKey="Bruns, Frank" sort="Bruns, Frank" uniqKey="Bruns F" first="Frank" last="Bruns">Frank Bruns</name>
</author>
</analytic>
<series><title level="j">Anticancer research</title>
<idno type="ISSN">0250-7005</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Amifostine (therapeutic use)</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Deglutition Disorders (chemically induced)</term>
<term>Deglutition Disorders (drug therapy)</term>
<term>Esophageal Stenosis (chemically induced)</term>
<term>Esophageal Stenosis (drug therapy)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Head and Neck Neoplasms (therapy)</term>
<term>Humans</term>
<term>Lymphedema (chemically induced)</term>
<term>Lymphedema (drug therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Radiation-Protective Agents (therapeutic use)</term>
<term>Radiotherapy (adverse effects)</term>
<term>Taste Disorders (chemically induced)</term>
<term>Taste Disorders (drug therapy)</term>
<term>Time Factors</term>
<term>Xerostomia (chemically induced)</term>
<term>Xerostomia (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Amifostine (usage thérapeutique)</term>
<term>Antinéoplasiques (effets indésirables)</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Radioprotecteurs (usage thérapeutique)</term>
<term>Radiothérapie (effets indésirables)</term>
<term>Sténose de l'oesophage ()</term>
<term>Sténose de l'oesophage (traitement médicamenteux)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Troubles de la déglutition ()</term>
<term>Troubles de la déglutition (traitement médicamenteux)</term>
<term>Troubles du goût ()</term>
<term>Troubles du goût (traitement médicamenteux)</term>
<term>Tumeurs de la tête et du cou ()</term>
<term>Xérostomie ()</term>
<term>Xérostomie (traitement médicamenteux)</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amifostine</term>
<term>Radiation-Protective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Deglutition Disorders</term>
<term>Esophageal Stenosis</term>
<term>Lymphedema</term>
<term>Taste Disorders</term>
<term>Xerostomia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Deglutition Disorders</term>
<term>Esophageal Stenosis</term>
<term>Lymphedema</term>
<term>Taste Disorders</term>
<term>Xerostomia</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Radiothérapie</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term>
<term>Sténose de l'oesophage</term>
<term>Troubles de la déglutition</term>
<term>Troubles du goût</term>
<term>Xérostomie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amifostine</term>
<term>Radioprotecteurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème</term>
<term>Mâle</term>
<term>Sténose de l'oesophage</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Troubles de la déglutition</term>
<term>Troubles du goût</term>
<term>Tumeurs de la tête et du cou</term>
<term>Xérostomie</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The late toxicities due to multimodal therapy of advanced head and neck cancers were analysed. The impact of cytoprotection with amifostine is the specific objective of this report.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17649803</PMID>
<DateCreated><Year>2007</Year>
<Month>07</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0250-7005</ISSN>
<JournalIssue CitedMedium="Print"><Volume>27</Volume>
<Issue>4A</Issue>
<PubDate><MedlineDate>2007 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.</ArticleTitle>
<Pagination><MedlinePgn>1953-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The late toxicities due to multimodal therapy of advanced head and neck cancers were analysed. The impact of cytoprotection with amifostine is the specific objective of this report.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 851 patients (717 men, 134 women) with head and neck cancer were included in this prospective study. Of these patients, 519/851 had received amifostine before radio(chemo)therapy, while 332 control patients had not received any kind of cytoprotection before irradiation. Primary radiochemotherapy was performed in 282 patients and adjuvant radiation was administered in 569. The follow-up examination was carried out at our outpatient department 21.4 months (median, range 2.3 to 149 months) after the primary therapy.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Late xerostomia was seen in 765/851 patients (89.9%). Altered taste was reported by 284/851 (33.5%). These symptoms were reduced significantly by amifostine. No influence was seen on interstitial lymph edema (48.4%), or stenosis of the cervical esophagus (20.4%). Secondary symptoms such as dysphagia (78.8%) also had a trend for reduction.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The administration of amifostine offers an opportunity to reduce selected long-term toxicities for survivors of head and neck cancer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Büntzel</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, Südharzkrankenhaus Nordhausen, Nordhausen, Germany. jens.buentzel@shk-ndh.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Glatzel</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mücke</LastName>
<ForeName>Ralph</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Micke</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bruns</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011837">Radiation-Protective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>M487QF2F4V</RegistryNumber>
<NameOfSubstance UI="D004999">Amifostine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004999" MajorTopicYN="N">Amifostine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003680" MajorTopicYN="N">Deglutition Disorders</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004940" MajorTopicYN="N">Esophageal Stenosis</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011837" MajorTopicYN="N">Radiation-Protective Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013651" MajorTopicYN="N">Taste Disorders</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014987" MajorTopicYN="N">Xerostomia</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>7</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>9</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>7</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17649803</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003585 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003585 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:17649803 |texte= Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17649803" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |